**Author’s response to reviews**

**Title:** Effectiveness and safety of exenatide in Korean patients with type 2 diabetes inadequately controlled with oral hypoglycemic agents: an observational study in a real clinical practice

**Authors:**
You-Cheol Hwang (khmcilyong@naver.com)
Ari Kim (ari.kim@astrazeneca.com)
Euna Jo (euna.jo@astrazeneca.com)
Yeoree Yang (lambten@gmail.com)
Jae-Hyoung Cho (drhopper@ikoob.com)
Byung-Wan Lee (bwanlee@yuhs.ac)

**Version:** 2  **Date:** 13 Oct 2017

**Author’s response to reviews:**

1. Please clarify the role of the funding body in the Funding section.

Corrections and Comments: We clarified the role of the funding body in the Funding section (line 10-12, page 13)

“This work was supported by a grant from AstraZeneca. The funder managed the data, and its representative was involved in the data analysis and preparation of manuscript. The funder had no role in study design and decision to publish”

2. Please represent authors' names using their full initials, not their full name, in the Authors’ Contributions section. If there are any duplicated initials, please differentiate them to make it clear that the initials refer to separate authors.

Corrections and Comments: We change the authors’ names from their full name to their full initials in the Authors’ Contributions section (line 19-23, page 13).

3. The individual contributions of ALL authors to the manuscript should be specified in the Authors’ Contributions section. Guidance and criteria for authorship can be found here:
Currently, Euna Jo and Yeoree Yang are not included in the Authors' Contributions section.

Corrections and Comments: We changed and augmented the Authors' contributions section to contain the all of the authors’ name (line 19-23, page 13).

4. Please include a statement in the Authors' contributions section to the effect that all authors have read and approved the manuscript, and ensure that this is the case.

Corrections and Comments: We added that comment at the last part of the Authors' contributions section (line 19-23, page 13).

5. Please include the full name of the ethics committee (and the institute to which it belongs to) that approved the study and the committee’s reference number if appropriate. Please include this information in the Ethics approval and consent to participate section.

Corrections and Comments: We added an additional table S1 to include the full name of the institute which the ethics committee belongs to and committee’s reference number. We included this information in the Ethics approval and consent to participate section (line 11, page 14).

6. Figures should be provided as separate files, and each figure of a manuscript should be submitted as a single file.

Comments: We resubmitted our figures with the separate files.

7. At this stage, please upload your manuscript as a single, final, clean version that does not contain any tracked changes, comments, highlights, strikethroughs or text in different colours. All relevant tables/figures/additional files should also be clean versions. Figures (and additional files) should remain uploaded as separate files.

Comments: We resubmitted our manuscripts followed by your instructions.